

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
June 17, 2021
MO HealthNet
VIA WEBEX ONLY

Committee Members Present:

Conrad Balcer, DO, Chair
Laura Kingsley, PharmD
Morgan Sperry, PharmD
Angeline Stanislaus, MD
Matthew Stinson, MD

Blake Shrouf, PharmD, Conduent
Geri Roling, RN, Wipro
Chelsea Pendleton, RN, BSN, Wipro
Valerie Schmitz, RN, BSN, Wipro
Sandy Kapur, PharmD, Conduent
Luke Boehmer, PharmD, Conduent

Jordan Feuerborn
K Gulley
Karen Floeder
Karen Malamut
Kathrin Kucharski
Kathryne Jensen
Ken Nicholson
Kurt

Committee Members Absent:

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Elizabeth Sissom, RN, Clinical Management
Lisa E. Smith, Program Development
Specialist
Carmen Burton, Administrative Assistant
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Denise Sappenfield, benefit Program Senior
Specialist
Alexi Moeller, PharmD Candidate 2022

Others Attending:

Aaron Shaw
Amy Aikins
Anabelle Keohane
Andrew Houck
Audrey Rattan
Bobbi Bentz
Brent Young
Brian Strickland
Brooke Wilkins
Camille Kerr
Carrie Davis
Chris Guenther
Dana Pipkin
David Cram
Elena Avello
Erin Hohman
Gina Heinen
Holly Budlong
James Baumann
Janis Pruett
Jessica Petrie
Joe Cirrincione
John Bullard

L Stout
Mandi Champ
Mark Kaiser
Matthew Bradley
Melissa Basil
Melissa DuVall
Michael Holmes
Michele Shirley
Phillip King
Ricki Roberson
Rob Kilo
Robert Firnberg
Roberto Pedraza
Ryan Hung
Sarica Klein
Scott Anderson
Sean Jones
Suzanne Morgan
Tami Sova
Tom Guyer
Tom Seignious

Contractors in Attendance:

Jennifer Colozza, PharmD, Conduent
Megan Fast, PharmD, Conduent
Karen Powell, PharmD, Conduent
Serena Barden, PharmD, BCPS, Conduent
April Ash, PharmD, Conduent

<p>Welcome, Introductions and Opening Remarks</p>	<p>Conrad Balcer, Board Chair, called the meeting to order.</p> <p>Joshua Moore introduced himself, along with Alexi Moeller, an UMKC pharmacy student with MHD, and facilitated the meeting on behalf of the MO HealthNet Division. Announcements also included the retirement of Jackie Hickman, the Drug Rebate Unit Supervisor, and the promotion of Kerri Ballew into the position.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the March 2021 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - Updates for upcoming in person meetings and expectations for Sept DPAC - April 2021 Eligibles by Group - July 2020 – April 2021 Expenditures by Enrollment Group - July 2020 – April 2021 Expenditures by Service - FY21 Pharmacy Spend vs July 2020 – April 2021 Total Medicaid Spend - FY21 July 2020 – June 2021 Pharmacy Expenditures - Top 4 Drug Classes per Fiscal Year 2021 - July 2020 – June 2021 Rare Disease Expenditures - FY19 – FYTD2021 Rare Disease Expenditures - Hepatitis C Elimination Plan Updates <ul style="list-style-type: none"> o July 1st implementation o Hepatitis C ShowMe ECHO Program o DSS website with progress highlights - 340B Reimbursement Modification <ul style="list-style-type: none"> o SPA approved June 2021 o Covered Outpatient Rule - High Risk Combinations Edit Updates <ul style="list-style-type: none"> o Increased utilization of Narcan = showing success in initiative; o Program integrity auditing is in place to prevent pharmacies from circumventing edit - Reminder: pharmacy copayments are waived now through the end of the public health emergency

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - Public comment provided by: <ul style="list-style-type: none"> o Scott Anderson with Regeneron Pharmaceuticals on Evkeeza o Elena Avello with Regeneron Pharmaceuticals on Regen-Cov o Andrew Houck with Chiesi USA on Bronchitol o Joseph Cirrincione with Otsuka on Abilify MyCite <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>

<p align="center">Clinical & Fiscal Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Ampyra Clinical Edit o Elagolix Clinical Edit o Gamifant Clinical Edit o Koselugo Clinical Edit o Luxturna Clinical Edit o Oxervate Clinical Edit o Reblozyl Clinical Edit o Synagis Clinical Edit o Tepezza Clinical Edit o Tolvaptan Clinical Edit o Zometa Clinical Edit - No public comment provided <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">CAR-T Cell Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Crysvita Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Duchenne Muscular Dystrophy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Kathrin Kucharski with Sarepta yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Entresto Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Extended Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">HBV Nucleotide Analog Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Imcivree Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Iron, Injectable Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Nulibry Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Oxazolidinone Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on previous criteria on Zyvox/linezolid – it was explained the previous clinical criteria is no longer in place. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Palynziq Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>PTH Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p style="text-align: center;">Verquvo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarifications discussed on the trial and failure with Entresto – it was explained there would be exceptions to this trial and failure with ineffective therapy or adverse reactions to Entresto. - Discussion on how savings with non-hospitalization might outweigh the cost of therapy was presented. - Public comment provided by <ul style="list-style-type: none"> o Karen Malamut and Ricki Roberson with Merck <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Zokinvy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Amylin Analogs o Antibiotics, Vaginal o Bile Salt Agents o Cephalosporin Agents o Electrolyte Depleting Agents, Phosphate Lowering o Electrolyte Depleting Agents, Potassium Lowering o Fluoroquinolone Agents, Oral o Insulin, Mixed o Insulin, Non-Analogs o Penicillin Agents o Sulfonylureas, Second Generation o Targeted Immune Modulators, IL6 Receptor Inhibitors o Thrombocytopenia Agents - Public comment provided by: <ul style="list-style-type: none"> o Sarica Klein with Dova on Doptelet in the Thrombocytopenia Agents PDL Edit <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Alpha-Glucosidase Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antibiotics, GI Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Antibiotics, Mupirocin Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antihyperuricemic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Benign Prostatic Hyperplasia (BPH) Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Biguanides & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Bone Ossification Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Colony Stimulating Factors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Cryopyrin-Associated Periodic Syndrome Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">DPP-IV Inhibitors & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Erythropoiesis Stimulating Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">GLP-1 Receptor Agonists & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion on adding Ozempic max dosing – the new weight loss agent hit the drug files this week so update to occur soon - Clarification was given on Bydureon still being listed as a PDL agent even though it has been discontinued – there is potential for claims as some pharmacies are using up their remaining stock - Public comment provided by: <ul style="list-style-type: none"> o Bobbi Bentz with Lily on Trulicity <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Growth Hormone Agents, Somatropin PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Insulin, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Insulin, Rapid Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">LHRH/GnRH Agents, Non-Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification provided on diagnosis for these agents – at this time, we do not - Public comment provided by: <ul style="list-style-type: none"> o Holy Budlong with Abbvie yielded time back o Janis Pruettt with Sunovion Pharmaceuticals on Orgovyx <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Macrolides PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Meglitinides PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Methotrexate Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Multiple Sclerosis Agents, Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Brooke Wilkins with Novartis on Kesimpta <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Multiple Sclerosis Agents, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Tami Sova with Biogen on Vumerity <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">SGLT2 Inhibitors & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Bobbi Bentz with Lily on Taltz <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Targeted Immune Modulators, IL23 Inhibitors & IL23/IL12 Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Targeted Immune Modulators, JAK Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was given on the Xeljanz solution prior authorization exclusions due to participant's weight/ age. - Public comment provided by: <ul style="list-style-type: none"> o James Bauman with Pfizer on Xeljanz solution <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Targeted Immune Modulators, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o David Cram with Takeda on Avsola <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Targeted Immune Modulators, TNF Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Mandi Champ with Amgen yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Tetracycline Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Thiazolidinediones & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Urinary Tract Antispasmodics PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and September meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>

<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 3rd Quarter 2021 (January, February, March) - Top 25 Drugs by Paid Number 3rd Quarter 2021 (January, February, March) - Call Center User Statistics May 2021 - CyberAccess Logging Information - New Drug Statistics
<p>Adjournment</p>	<p>Angeline Stanislaus motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person for MHD, board members, contractors, and WebEx for all others) on Thursday, September 16, 2021.</p>

Roll Call for June 17, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
December 2020 Minutes	Y	Y	MY	SY	Y
New Drug Review	Y	SY	Y	Y	MY
Clinical/Fiscal Edit – No Changes	Y	Y	MY	Y	SY
CAR-T Cell Clinical Edit	Y	Y	Y	SY	MY
Crysvita Clinical Edit	Y	Y	Y	MY	SY
Duchenne Muscular Dystrophy Clinical Edit	Y	Y	Y	MY	SY
Entresto Clinical Edit	Y	Y	Y	MY	SY
Extended Supply Fiscal Edit	Y	MY	Y	SY	Y
HBV Nucleotide Analog Clinical Edit	Y	SY	Y	MY	Y
Imcivree Clinical Edit	Y	Y	Y	MY	SY
Iron, Injectable Clinical Edit	Y	SY	Y	Y	MY
Nulibry Clinical Edit	Y	Y	Y	SY	MY
Oxazolidinone Fiscal Edit	Y	Y	Y	SY	MY
Palynziq Clinical Edit	Y	Y	Y	SY	MY

Roll Call for June 17, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
PTH Agents Clinical Edit	Y	MY	Y	SY	Y
Verquvo Clinical Edit	Y	Y	Y	MY	SY
Zokinvy Clinical Edit	Y	MY	Y	SY	Y
Preferred Drug List Edits With No Annual Changes	Y	MY	Y	Y	SY
Thrombocytopenia Agents PDL Edit	Y	Y	SY	MY	Y
Alpha-Glucosidase Inhibitors PDL Edit	Y	Y	Y	SY	MY
Antibiotics, GI Oral PDL Edit	Y	MY	Y	Y	SY
Antibiotics, Mupirocin Topical PDL Edit	Y	Y	Y	SY	MY
Antihyperuricemic Agents PDL Edit	Y	SY	Y	MY	Y
Benign Prostatic Hyperplasia (BPH) Agents PDL Edit	Y	SY	MY	Y	Y
Biguanides & Combinations PDL Edit	Y	MY	Y	SY	Y
Bone Ossification Agents PDL Edit	Y	Y	Y	MY	SY
Colony Stimulating Factors PDL Edit	Y	SY	Y	Y	MY

Roll Call for June 17, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
Cryopyrin-Associated Periodic Syndrome Agents PDL Edit	Y	Y	Y	MY	SY
DPP-IV Inhibitors & Combinations PDL Edit	Y	Y	SY	MY	Y
Erythropoiesis Stimulating Agents PDL Edit	Y	MY	Y	Y	SY
GLP-1 Receptor Agonists & Combinations PDL Edit	Y	MY	Y	SY	Y
Growth Hormone Agents, Somatropin PDL Edit	Y	MY	Y	Y	SY
Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit	Y	Y	SY	MY	Y
Insulin, Long Acting PDL Edit	Y	Y	MY	SY	Y
Insulin, Rapid Acting PDL Edit	Y	Y	SY	MY	Y
LHRH/GnRH Agents, Non-Oral PDL Edit	Y	SY	Y	MY	Y
Macrolides PDL Edit	Y	MY	Y	Y	SY
Meglitinides PDL Edit	Y	SY	Y	MY	Y
Methotrexate Agents PDL Edit	Y	SY	Y	Y	MY

Roll Call for June 17, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
Multiple Sclerosis Agents, Injectable PDL Edit	Y	SY	Y	MY	Y
Multiple Sclerosis Agents, Oral PDL Edit	Y	Y	SY	MY	Y
SGLT2 Inhibitors & Combinations PDL Edit	Y	SY	Y	MY	Y
Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit	Y	Y	Y	MY	SY
Targeted Immune Modulators, IL23 Inhibitors & IL23/IL12 Inhibitors PDL Edit	Y	Y	SY	MY	Y
Targeted Immune Modulators, JAK Inhibitors PDL Edit	Y	MY	Y	SY	Y
Targeted Immune Modulators, Select Agents PDL Edit	Y	SY	Y	MY	Y
Targeted Immune Modulators, TNF Inhibitors PDL Edit	Y	MY	SY	Y	Y
Tetracycline Agents PDL Edit	Y	Y	SY	MY	Y
Thiazolidinediones & Combinations PDL Edit	Y	SY	Y	MY	Y
Urinary Tract Antispasmodics PDL Edit	Y	SY	MY	Y	Y

Roll Call for June 17, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
Motion to Close	Y	SY	Y	MY	Y
Adjournment	Y	Y	MY	Y	SY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain